Synopsis: A small cap company’s shares rose over 10 percent in today’s trading session after announcing Q2 results.
A small cap company that engaged in the manufacture, distribution, and maintenance of medical equipment in India and abroad is in the spotlight today after posting Q2FY26 results. Read the article below for detailed insights into its performance.
With a market capitalization of Rs. 7,483.87 crore, the shares of Fischer Medical Ventures Limited were trading at Rs. 115.40, up by 5.77 percent from its previous closing price of Rs. 109.10. In today’s trading session it has touched an intraday high of Rs. 121.45, implying an upside of 11.32 percent from previous close price.
Q2FY26 Results
Fischer Medical Ventures Limited reported Rs. 86.31 crore in revenue for the second quarter of FY26, a 117.62 percent increase over the Rs. 39.66 crore for the same period in FY25. It increased by 268.22 percent as compared to Rs. 23.44 crore in Q1 FY26.
The company’s EBITDA for Q2 FY26 stood at Rs. 16.26 crore, up by 281.69 percent from Rs. 4.26 crore in Q1 FY26, and rose by 3,218.37 percent from Rs. 0.49 crore in Q2 FY25.
The consolidated net profit for the second quarter of FY26 was Rs. 13.9 crore, which was 177.45 percent higher than the Rs. 5.01 crore reported in the previous quarter and increased by 4,693.10 percent from Rs. 0.29 crore in Q2 FY25. Profit growth was also reflected in earnings per share (EPS), which increased to approximately Rs. 2.15 in Q2 FY26 from Rs. 0.77 in Q1 FY26 and Rs. 0.76 in Q2 FY25.
Operational Highlights
The company acquired a landmark property in Malaysia to develop an Integrated Regional Healthcare Hub and partnered with the City of Jember, Indonesia, for a USD 10 million AI-powered X-ray initiative supporting TB elimination by 2030. It also achieved full licensing in Indonesia, enabling participation in government tenders, and expanded diagnostic imaging in India with new MRI installations in Chennai and Sikkim.
Management View
According to Chairman Ravindran Govindan, Fischer Medical Ventures delivered a strong Q2 performance with sharp improvement in profitability and operations, driven by scalable business, better product realization, and wider adoption of its technology. He highlighted that Fischer is well-positioned in India’s fast-growing MedTech sector and aims to sustain growth through AI-led diagnostics, new product launches, and expansion across Southeast Asia.
About the company
Fischer Medical Ventures Limited, headquartered in Chennai and incorporated in 1993, is engaged in the manufacture, distribution, leasing, and maintenance of medical equipment in India and abroad. The company offers a wide range of products including MRI and CT scan systems, preventive health kiosks, e-health access points, handheld X-ray devices, cancer and TB screening solutions, spincare technology, nutraceuticals, and mental health and contactless screening solutions.
A return on equity (ROE) of about 0.70 percent, a return on capital employed (ROCE) of about 1.08 percent and debt to equity ratio at 0.25 demonstrate the company’s financial position. At the moment, the company’s P/E ratio is 370x which is higher as compared to its industry P/E 49.8x.
Shareholding Pattern
As of September 2025, the company’s shareholding pattern shows that promoters hold 61.8 percent of the total equity, indicating strong promoter ownership. Foreign Institutional Investors (FIIs) hold 5.57 percent, while Domestic Institutional Investors (DIIs) own 1.42 percent. The public shareholding stands at 31.22 percent, reflecting a healthy level of retail and institutional participation in the company.
Written By Akshay Sanghavi
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
